McKesson Corporation (MCK) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

McKesson Corporation (MCK) Healthcare & Pipeline Overview

McKesson Corporation, a global healthcare services leader, distributes pharmaceuticals and provides medical solutions. Operating through four segments, including U.S. Pharmaceutical and Medical-Surgical Solutions, McKesson connects pharmacies, providers, payers, and biopharma companies. With a $103B market cap, McKesson serves a critical role in healthcare supply chains.

What Is the Investment Thesis for MCK?

With a market capitalization of $103B and a P/E ratio of 23.47, McKesson demonstrates financial stability. The company's consistent performance is underpinned by its U.S. Pharmaceutical segment, which benefits from the steady demand for pharmaceutical products. Growth catalysts include the expansion of its RxTS segment, focusing on medication adherence solutions, and strategic acquisitions to enhance its international presence. However, investors may want to evaluate potential risks such as regulatory changes in the healthcare industry and competitive pressures from other distributors. The company's low beta of 0.42 suggests lower volatility compared to the market, making it a noteworthy option for risk-averse investors seeking stable returns. McKesson's dividend yield of 0.43% provides a modest income component to the investment.

Based on FMP financials and quantitative analysis

MCK Key Highlights

Market Cap of $103B reflects McKesson's significant presence in the healthcare distribution market.

• P/E Ratio of 23.47 indicates a reasonable valuation relative to its earnings.
• Gross Margin of 3.6% demonstrates efficiency in managing the cost of goods sold.
• Dividend Yield of 0.43% provides a modest income stream for investors.
• Beta of 0.42 suggests lower volatility compared to the broader market, indicating a relatively stable investment.

Who Are MCK's Competitors?

MCK is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are MCK's Key Strengths?

Extensive distribution network and supply chain infrastructure.

• Diversified business segments across pharmaceutical and medical-surgical solutions.
• Strong relationships with pharmaceutical manufacturers and healthcare providers.
• Established market position and brand recognition.

What Are MCK's Weaknesses?

Relatively low profit margin compared to some competitors (1.2%).

• Exposure to regulatory changes and pricing pressures in the healthcare industry.
• Dependence on key suppliers and customers.
• Potential for supply chain disruptions.

What Could Drive MCK Stock Higher?

MCK catalyst: Expansion of the RxTS segment, focusing on medication adherence solutions, is expected to drive revenue growth.

• Potential acquisitions in international markets to expand McKesson's geographic footprint.
• Increased demand for specialty pharmaceuticals and biosimilars is expected to boost sales.
• Leveraging data analytics to improve healthcare outcomes and drive efficiency.
• Development and launch of new technology solutions for healthcare providers.

What Are the Key Risks for MCK?

Insider selling — insiders were net sellers of roughly $6.3M recently.

• Regulatory changes in the healthcare industry could impact pricing and reimbursement.
• Intense competition from other pharmaceutical distributors and healthcare providers.
• Cybersecurity threats and data breaches could disrupt operations and damage reputation.
• Pricing pressures from payers and government regulations.
• Product recalls and liability claims.

What Are the Growth Opportunities for MCK?

• Expansion of Prescription Technology Solutions (RxTS): McKesson's RxTS segment offers significant growth potential by addressing medication adherence challenges. The market for medication adherence solutions is expanding as healthcare providers and payers seek to improve patient outcomes and reduce costs. By leveraging technology to connect pharmacies, providers, and biopharma companies, McKesson can capture a larger share of this market. This expansion aligns with the broader trend of digital health solutions and personalized medicine, offering a competitive advantage.
• Strategic Acquisitions in International Markets: McKesson can drive growth through strategic acquisitions in international markets, particularly in Europe and Canada. Expanding its presence in these regions allows McKesson to tap into new customer bases and diversify its revenue streams. These acquisitions can also provide access to new technologies and service offerings, enhancing McKesson's overall competitiveness. The timeline for these acquisitions depends on market conditions and regulatory approvals, but the long-term potential is substantial.
• Increased Focus on Specialty Pharmaceuticals: The specialty pharmaceutical market is growing rapidly, driven by the development of innovative therapies for complex diseases. McKesson can capitalize on this trend by expanding its distribution and support services for specialty pharmaceuticals. This includes providing specialized handling, storage, and logistics services, as well as offering patient support programs. By becoming a preferred partner for specialty pharmaceutical manufacturers, McKesson can secure a significant share of this high-growth market.
• Enhancement of Medical-Surgical Solutions: McKesson's Medical-Surgical Solutions segment can be enhanced by expanding its product offerings and improving its logistics capabilities. This includes offering a wider range of medical supplies and equipment, as well as implementing advanced supply chain management technologies. By providing healthcare providers with a comprehensive suite of products and services, McKesson can strengthen its relationships and increase its market share. The timeline for these enhancements is ongoing, with continuous investments in technology and infrastructure.
• Leveraging Data Analytics for Improved Healthcare Outcomes: McKesson can leverage its extensive data assets to improve healthcare outcomes and drive efficiency. By analyzing data on medication usage, patient demographics, and healthcare costs, McKesson can identify opportunities to optimize treatment plans, reduce waste, and improve patient adherence. This data-driven approach can also help healthcare providers make more informed decisions and improve the quality of care. The implementation of advanced data analytics capabilities is an ongoing process, with continuous investments in technology and expertise.

What Are MCK's Competitive Advantages?

• Extensive distribution network provides a significant logistical advantage.
• Strong relationships with pharmaceutical manufacturers and healthcare providers.
• Comprehensive suite of services creates a sticky customer base.
• Scale and scope provide cost advantages and economies of scale.

What Does MCK Do?

Founded in 1833 and headquartered in Irving, Texas, McKesson Corporation has evolved into a global healthcare services giant. Initially a drug store, the company expanded its operations to include pharmaceutical distribution and healthcare solutions. McKesson operates through four key segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes a wide array of pharmaceutical products, including branded, generic, and specialty drugs, while also offering technology and business solutions to specialty practices and pharmacies. The International segment extends McKesson's reach to wholesale, institutional, and retail customers across 13 European countries and Canada. The Medical-Surgical Solutions segment focuses on providing medical-surgical supply distribution and logistics services to healthcare providers. Lastly, the RxTS segment connects pharmacies, providers, payers, and biopharma companies, delivering innovative access and adherence solutions. McKesson's comprehensive suite of services and extensive distribution network positions it as a critical player in the healthcare ecosystem, facilitating the efficient delivery of pharmaceuticals and healthcare solutions to patients worldwide.

What Products and Services Does MCK Offer?

• Distributes branded, generic, and specialty pharmaceutical drugs.
• Provides medical-surgical supply distribution and logistics services.
• Offers practice management, technology, and clinical support solutions to healthcare providers.
• Connects pharmacies, providers, payers, and biopharma companies.
• Delivers innovative access and adherence solutions for patients.
• Provides consulting, outsourcing, and technological services to pharmacies.
• Offers third-party logistics and wholesale distribution support solutions.

How Does MCK Make Money?

• Distribution of pharmaceutical products to pharmacies and healthcare providers.
• Provision of medical-surgical supplies and equipment.
• Offering technology and business solutions to healthcare practices.
• Generating revenue through service fees and product sales.

What Industry Does MCK Operate In?

McKesson Corporation operates within the medical distribution industry, a critical component of the broader healthcare sector. The industry is characterized by increasing demand for pharmaceuticals and medical supplies, driven by an aging population and advancements in medical treatments. McKesson competes with companies like CVS Health Corporation (CVS) and Bristol-Myers Squibb Company (BMY). The market is also influenced by regulatory changes, pricing pressures, and the increasing importance of supply chain efficiency. The global healthcare market is projected to continue growing, presenting opportunities for McKesson to expand its market share and service offerings.

Who Are MCK's Key Customers?

• Pharmacies (retail and specialty)
• Hospitals and health systems
• Physician practices and clinics
• Biopharmaceutical companies
• Long-term care facilities

McKesson Corporation Financial Trajectory

McKesson Corporation (MCK) reported $105.38B in revenue for Q1 FY2027, reflecting 9.4% growth compared to the prior quarter. The company recorded net income of $614.0M, with diluted EPS of $5.15. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, MCK averaged $9.34 in diluted EPS.

Company Profile

McKesson Corporation operates in the Medical - Distribution industry within the Healthcare sector. It is headquartered in Irving, US. The company is led by CEO Brian S. Tyler. MCK has traded publicly since 1994.

How McKesson Corporation Is Valued

McKesson Corporation carries a market capitalization of $103B, placing it in the large-cap category. Analyst price targets span from $845.00 to $1050.00, with a consensus of $953.00. At the current price of $880.90, that implies approximately 8% upside potential. Relative to its peer group, MCK's quantitative score of 88/100 is roughly in line with the peer average of 85/100.

Return on assets is 5.8%, showing how much profit it generates from its asset base. MCK trades at a trailing price-to-earnings ratio of 23.47, roughly in line with the Healthcare sector average of ~21.50x. Its free cash flow yield is 6.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.85 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 5.1%, the inverse of the P/E and a quick read on earnings relative to price.

McKesson Corporation's Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 5.83 places it in the safe zone, indicating low near-term bankruptcy risk.

McKesson Corporation has beaten Wall Street's EPS estimate in 7 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 2.1% above estimates on average.

Over the past six months, McKesson Corporation insiders filed 13 SEC Form 4 transactions — 2 sales and 11 purchases. On net that is roughly 6K shares disposed (about $6.3M), a signal worth weighing alongside the fundamentals.

MCK Financials

MCK earnings history & estimates →

MCK Latest News

MCK Analyst Consensus

MCK MoonshotScore

Latest McKesson Corporation Analysis

What Investors Ask About McKesson Corporation (MCK) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources